AstraZeneca Unburdens Itself Of Brodalumab
This article was originally published in Scrip
AstraZeneca plc has managed to offload the dermatology candidate brodalumab to Valeant Pharmaceuticals International Inc following Amgen's decision to pull out of a co-development deal earlier this year. Amgen made the move owing to potential side effect issues, with suicidal thoughts being linked to brodalumab administration during clinical development, despite evidence of efficacy.
Register for our free email digests: